Evidence for dopaminergic control of thyrotrophin secretion in man.
After administration of the dopamine-receptor-blocking drug, metoclopramide (10 mg orally), there is significant release of thyrotrophin (T.S.H.) in hypothyroid patients which is not evident in euthyroid subjects. This is not due to spontaneous fluctuation in basal T.S.H. levels, and it indicates inhibitory dopaminergic control of T.S.H. release in man. The lack of significant T.S.H. release in euthyroid subjects may be due to the inhibitory effects of normal circulating levels of T3 and T4 on T.S.H. release. The T.S.H. response in hypothyroidism is significantly correlated with both T3 and T4 levels, suggesting suppression of this inhibitory pathway in increasingly severe hypothyroidism.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D005260:Female; D006801:Humans; D007037:Hypothyroidism / Q000503:physiopathology*; D008297:Male; D008787:Metoclopramide / Q000008:administration & dosage / Q000494:pharmacology; D008875:Middle Aged; D010901:Pituitary Function Tests; D010903:Pituitary Gland, Anterior / Q000503:physiopathology; D011954:Receptors, Dopamine / Q000187:drug effects / Q000502:physiology*; D013960:Thyroid Function Tests; D013961:Thyroid Gland / Q000503:physiopathology; D013972:Thyrotropin / Q000037:antagonists & inhibitors / Q000378:metabolism*; D013974:Thyroxine / Q000502:physiology; D014284:Triiodothyronine / Q000502:physiology
D011954:Receptors, Dopamine; D014284:Triiodothyronine; D013972:Thyrotropin; D008787:Metoclopramide; D013974:Thyroxine